Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NYSE:ANRO NASDAQ:BOLD NASDAQ:EQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.50+0.4%$2.40$0.80▼$3.42$102.71M-0.89165,131 shs93,204 shsANROAlto Neuroscience$3.83-3.0%$3.33$1.60▼$15.04$103.74M1.91242,274 shs69,701 shsBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.74M-1.2275,757 shs96,520 shsEQEquillium$1.53-6.1%$1.07$0.27▼$2.35$91.04M1.583.35 million shs658,638 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+1.22%+13.18%-0.40%+60.65%+19.14%ANROAlto Neuroscience+4.93%+4.37%+25.08%+74.34%-71.68%BOLDBoundless Bio+0.44%-0.43%-1.72%+9.05%-69.63%EQEquillium-4.68%-10.93%+42.98%+405.43%+89.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.50+0.4%$2.40$0.80▼$3.42$102.71M-0.89165,131 shs93,204 shsANROAlto Neuroscience$3.83-3.0%$3.33$1.60▼$15.04$103.74M1.91242,274 shs69,701 shsBOLDBoundless Bio$1.14-50.4%$59.97$1.00▼$4.72$25.74M-1.2275,757 shs96,520 shsEQEquillium$1.53-6.1%$1.07$0.27▼$2.35$91.04M1.583.35 million shs658,638 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+1.22%+13.18%-0.40%+60.65%+19.14%ANROAlto Neuroscience+4.93%+4.37%+25.08%+74.34%-71.68%BOLDBoundless Bio+0.44%-0.43%-1.72%+9.05%-69.63%EQEquillium-4.68%-10.93%+42.98%+405.43%+89.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.50Moderate Buy$5.50120.00% UpsideANROAlto Neuroscience 2.57Moderate Buy$8.50121.87% UpsideBOLDBoundless Bio 2.25Hold$3.50207.02% UpsideEQEquillium 2.00Hold$1.00-34.64% DownsideCurrent Analyst Ratings BreakdownLatest BOLD, ANRO, EQ, and ANEB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/11/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.007/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/26/2025ANROAlto NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AANROAlto NeuroscienceN/AN/AN/AN/A$5.62 per shareN/ABOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/AEQEquillium$41.10M2.21N/AN/A$0.54 per share2.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/24/2025 (Estimated)ANROAlto Neuroscience-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)BOLDBoundless Bio-$65.36MN/AN/AN/AN/AN/A-44.79%-34.24%N/AEQEquillium-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%11/12/2025 (Estimated)Latest BOLD, ANRO, EQ, and ANEB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/24/2025Q4 2025ANEBAnebulo Pharmaceuticals-$0.05N/AN/AN/AN/AN/A8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/A8/13/2025Q2 2025ANROAlto Neuroscience-$0.57-$0.65-$0.08-$0.65N/AN/A8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AANROAlto NeuroscienceN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29ANROAlto Neuroscience0.1818.4318.43BOLDBoundless Bio0.3914.0814.08EQEquilliumN/A1.651.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%ANROAlto NeuroscienceN/ABOLDBoundless BioN/AEQEquillium27.05%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%ANROAlto NeuroscienceN/ABOLDBoundless Bio21.10%EQEquillium30.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million7.97 millionNot OptionableANROAlto NeuroscienceN/A27.08 millionN/AN/ABOLDBoundless Bio20722.39 million17.66 millionNo DataEQEquillium4059.50 million41.47 millionNot OptionableBOLD, ANRO, EQ, and ANEB HeadlinesRecent News About These CompaniesEquillium, Inc. (NASDAQ:EQ) Short Interest UpdateSeptember 16 at 8:40 PM | marketbeat.comEquillium files to sell 52.63M shares of common stock for holdersSeptember 9, 2025 | msn.comEquillium (NASDAQ:EQ) Upgraded at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comEquillium Regains Nasdaq Compliance with Bid Price RuleSeptember 4, 2025 | tipranks.comEquillium, Inc. (NASDAQ:EQ) Short Interest Up 666.5% in AugustSeptember 4, 2025 | marketbeat.comEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2025 | finance.yahoo.comEquillium (NASDAQ:EQ) Trading Down 4.7% - Should You Sell?August 31, 2025 | marketbeat.comEquillium to Participate in the Cantor Global Healthcare Conference 2025August 29, 2025 | businesswire.comEquillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UCAugust 28, 2025 | seekingalpha.comEquillium price target lowered to $4 from $8 at JefferiesAugust 20, 2025 | msn.comEquillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the ClinicAugust 11, 2025 | finance.yahoo.comEquillium Secures $30 Million in Private PlacementAugust 11, 2025 | tipranks.comEquillium Shares Drop 12.4% After Unveiling Cryptocurrency Treasury StrategyAugust 4, 2025 | msn.comSpotlight On 3 Promising Penny Stocks With Over $20M Market CapAugust 4, 2025 | finance.yahoo.comEquillium stock falls after announcing cryptocurrency treasury strategyAugust 4, 2025 | au.investing.comEquillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve StrategyAugust 4, 2025 | businesswire.comInterleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightJuly 11, 2025 | finance.yahoo.comEquillium, Inc. (EQ) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.com4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsightJune 14, 2025 | medindia.netMEquillium expands equity incentive plan by 1.78 million sharesMay 24, 2025 | investing.comEquillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsMay 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Intel's New Buyers Mean Good News for Taiwan Semiconductor StockBy Gabriel Osorio-Mazilli | August 22, 2025Equal Weight ETFs: Hidden Upside in Today’s MarketBy Gabriel Osorio-Mazilli | August 23, 2025Taiwan Semiconductor Falls on China News—Buy The Dip?By Gabriel Osorio-Mazilli | September 3, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025BOLD, ANRO, EQ, and ANEB Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.50 +0.01 (+0.40%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.02 (-0.60%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Alto Neuroscience NYSE:ANRO$3.83 -0.12 (-3.01%) Closing price 03:59 PM EasternExtended Trading$3.93 +0.10 (+2.69%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Equillium NASDAQ:EQ$1.53 -0.10 (-6.13%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.98%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
